Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$6.33 USD

6.33
278,414

-0.21 (-3.21%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $6.33 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 36% (158 out of 246)

Industry: Medical - Instruments

Zacks News

Zacks Equity Research

Inogen (INGN) Up 9.7% Since Last Earnings Report: Can It Continue?

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Here's Why You Should Hold On to Inogen (INGN) Stock for Now

Inogen (INGN) expects to report a loss per share in the first quarter of 2020.

Zacks Equity Research

Inogen's (INGN) Q4 Earnings Miss, Revenues Top Estimates

Inogen (INGN) sees segmental softness in the fourth quarter.

Zacks Equity Research

Inogen (INGN) Q4 Earnings Miss Estimates

Inogen (INGN) delivered earnings and revenue surprises of -36.36% and 0.02%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Moving Average Crossover Alert: Inogen

Inogen, Inc. (INGN) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.

Zacks Equity Research

New Strong Sell Stocks for January 31st

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today

Zacks Equity Research

Inogen (INGN) Announces Preliminary Q4 Results, Slashes View

Inogen (INGN) expects direct-to-consumer sales to be its fastest-growing channel in 2020.

Zacks Equity Research

Inogen (INGN) Up 7.2% Since Last Earnings Report: Can It Continue?

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Inogen's (INGN) Q3 Earnings and Revenues Beat Estimates

Softness in domestic and international business-to-business revenues impact Inogen's (INGN) Q3 results.

Zacks Equity Research

Inogen (INGN) Q3 Earnings and Revenues Top Estimates

Inogen (INGN) delivered earnings and revenue surprises of 34.78% and 0.42%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Why Is Inogen (INGN) Down 5.9% Since Last Earnings Report?

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Inogen (INGN) Q2 Earnings Miss Estimates, 2019 View Lowered

Inogen (INGN) gains from international revenues in Q2; slashes 2019 guidance.

Zacks Equity Research

Inogen (INGN) Misses Q2 Earnings and Revenue Estimates

Inogen (INGN) delivered earnings and revenue surprises of -10.00% and -5.55%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Earnings Preview: Inogen (INGN) Q2 Earnings Expected to Decline

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Inogen (INGN) Down 6.8% Since Last Earnings Report: Can It Rebound?

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

Inogen (INGN) Earnings Miss Estimates in Q1, View Lowered

Inogen (INGN) slashes revenue and net income guidance for 2019.

Zacks Equity Research

Inogen (INGN) to Report Q1 Earnings: What's in the Offing?

Inogen's (INGN) first-quarter 2019 results are expected to get a boost from product launches.

Zacks Equity Research

Why the Earnings Surprise Streak Could Continue for Inogen (INGN)

Inogen (INGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

Inogen (INGN) Launches One G5 Portable Oxygen Concentrator

Inogen's (INGN) product launch is in line with the company's strategy of providing innovative and long-term oxygen therapy to patients in need of respiratory aid.

Zacks Equity Research

Inogen (INGN) Down 12.9% Since Last Earnings Report: Can It Rebound?

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Kevin Cook headshot

Bull of the Day: DexCom (DXCM)

Diabetes care goes beyond the finger prick to streaming digital data with this rapidly growing innovator

Zacks Equity Research

Inogen's Prospects in Europe Solid Amid Trade-Related Tension

Inogen's (INGN) business-to-business unit sees strength in Europe.

Zacks Equity Research

Inogen (INGN) Q4 Earnings Beat Estimates, Rental Revenues Up

Inogen (INGN) gains from solid direct-to-consumer revenues in Q4; strong business-to-business revenues in the United States.